TuHURA Biosciences Files 8-K on Financials
Ticker: HURA · Form: 8-K · Filed: Nov 14, 2025 · CIK: 1498382
Sentiment: neutral
Topics: financial-reporting, company-update
TL;DR
TuHURA Bio filed an 8-K on Nov 14th covering financials and exhibits. Formerly Kintara.
AI Summary
TuHURA Biosciences, Inc. filed an 8-K on November 14, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The company, formerly known as Kintara Therapeutics, Inc., is incorporated in Nevada and headquartered in Tampa, Florida.
Why It Matters
This filing provides investors with crucial updates on TuHURA Biosciences' financial health and operational status, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and exhibits, not indicating any immediate adverse events.
Key Players & Entities
- TuHURA Biosciences, Inc. (company) — Registrant
- November 14, 2025 (date) — Date of earliest event reported
- Kintara Therapeutics, Inc. (company) — Former company name
- Nevada (jurisdiction) — State of incorporation
- Tampa, Florida (location) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
When was this 8-K filed?
The report was filed on November 14, 2025.
What was TuHURA Biosciences, Inc. formerly known as?
The company was formerly known as Kintara Therapeutics, Inc.
Where are TuHURA Biosciences, Inc.'s principal executive offices located?
The principal executive offices are located at 10500 University Center Dr., Suite 110, Tampa, Florida 33612.
What is the Standard Industrial Classification (SIC) code for TuHURA Biosciences, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-11-14 07:10:26
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HURA The Nasdaq
Filing Documents
- hura-20251114.htm (8-K) — 51KB
- hura-ex99_1.htm (EX-99.1) — 42KB
- img112559081_0.jpg (GRAPHIC) — 7KB
- 0001193125-25-281522.txt ( ) — 222KB
- hura-20251114.xsd (EX-101.SCH) — 30KB
- hura-20251114_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 14, 2025, TuHURA Biosciences, Inc. (the "Company" or "TuHURA") issued a press release reporting its financial results for the three months ended September 30, 2025, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein The information contained in this Current Report, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed "filed" for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Document 99.1 Press Release, dated November 14, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TUHURA BIOSCIENCES, INC. Date: November 14, 2025 By: /s/ Dan Dearborn Name: Dan Dearborn Title: Chief Financial Officer